[HTML][HTML] Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
N Albinger, J Hartmann, E Ullrich - Gene therapy, 2021 - nature.com
Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful
immunotherapeutic tools for combating hematological diseases confronted with pressing …
immunotherapeutic tools for combating hematological diseases confronted with pressing …
Driving CAR T-cells forward
HJ Jackson, S Rafiq, RJ Brentjens - Nature reviews Clinical oncology, 2016 - nature.com
The engineered expression of chimeric antigen receptors (CARs) on the surface of T cells
enables the redirection of T-cell specificity. Early clinical trials using CAR T cells for the …
enables the redirection of T-cell specificity. Early clinical trials using CAR T cells for the …
[PDF][PDF] Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta
A Griciuc, A Serrano-Pozo, AR Parrado, AN Lesinski… - Neuron, 2013 - cell.com
The transmembrane protein CD33 is a sialic acid-binding immunoglobulin-like lectin that
regulates innate immunity but has no known functions in the brain. We have previously …
regulates innate immunity but has no known functions in the brain. We have previously …
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
SS Kenderian, M Ruella, O Shestova, M Klichinsky… - Leukemia, 2015 - nature.com
Patients with chemo-refractory acute myeloid leukemia (AML) have a dismal prognosis.
Chimeric antigen receptor T (CART) cell therapy has produced exciting results in CD19+ …
Chimeric antigen receptor T (CART) cell therapy has produced exciting results in CD19+ …
[HTML][HTML] Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
Owing to the more recent positive results with the anti-CD33 immunotoxin gemtuzumab
ozogamicin, therapy against acute myeloid leukemias (AMLs) targeting CD33 holds many …
ozogamicin, therapy against acute myeloid leukemias (AMLs) targeting CD33 holds many …
[HTML][HTML] Neutrophils: need for standardized nomenclature
E McKenna, AU Mhaonaigh, R Wubben… - Frontiers in …, 2021 - frontiersin.org
Neutrophils are the most abundant innate immune cell with critical anti-microbial functions.
Since the discovery of granulocytes at the end of the nineteenth century, the cells have been …
Since the discovery of granulocytes at the end of the nineteenth century, the cells have been …
The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9
R Beatson, V Tajadura-Ortega, D Achkova, G Picco… - Nature …, 2016 - nature.com
Siglec-9 is a sialic-acid-binding lectin expressed predominantly on myeloid cells. Aberrant
glycosylation occurs in essentially all types of cancers and results in increased sialylation …
glycosylation occurs in essentially all types of cancers and results in increased sialylation …
Ocular adverse events associated with antibody–drug conjugates in human clinical trials
This article reviews ocular adverse events (AEs) reported in association with administration
of antibody–drug conjugates (ADCs) in human clinical trials. References reporting ocular …
of antibody–drug conjugates (ADCs) in human clinical trials. References reporting ocular …
[HTML][HTML] Radiolabeled antibodies for cancer imaging and therapy
Simple Summary Monoclonal antibodies (mAbs) have the ability to specifically target tumor-
cell antigens. This unique property has led to their use in the delivery of radioisotopes to …
cell antigens. This unique property has led to their use in the delivery of radioisotopes to …
[HTML][HTML] The expansion of targetable biomarkers for CAR T cell therapy
MH Townsend, G Shrestha, RA Robison… - Journal of Experimental & …, 2018 - Springer
Biomarkers are an integral part of cancer management due to their use in risk assessment,
screening, differential diagnosis, prognosis, prediction of response to treatment, and …
screening, differential diagnosis, prognosis, prediction of response to treatment, and …